

Willingsford Ltd

Contact: Frank Sams-Dodd



Phone: 023 8081 2325

E-mail: contact@willingsford.com

Website: www.willingsford.com

Based near Totton, Willingsford are behind SertaSil: a novel and innovative medical device for advanced wound care, which breaks with traditional approaches. It is a white powder to be applied directly to the wound surface once daily for 3-5 days.

SertaSil only needs to be covered by a light gauze dressing and is simple and fast to use. The product removes dead tissue and infections, including antibiotic resistant infections from the wound. It is effective on abscesses, post-surgical, trauma and chronic wounds, including diabetic foot, venous leg and pressure ulcers, and burns. It has been evaluated in a clinical study with 266 patients.



Benefits to using this treatment above and beyond those currently in use include a 60% reduction in time to achieve a clean wound. In addition data has show a 30% reduction in the number of bed days with the resulting advantages of a faster return to work and normal life. At an estimated £510 per bed day in the NHS, this has scope to save the Health Service considerable sums.

Following certification for the human market, SertaSil will be launched first in the UK, then EU and finally worldwide. Their future UK distributor has been identified and collaborative preparations for launch in the UK are already underway.

The global advanced wound care market was almost £12 billion in 2011 and the growth potential of the company is therefore considerable.

